Skip to content

Novo's CagriSema Cut Weight About 21% at Two Lower Doses in Phase 3 REDEFINE 9 Trial

November 15, 2026 · 7 min

Show notes

Novo Nordisk reported full results from REDEFINE 9, the first Phase 3 weight-management trial of its investigational once-weekly injection CagriSema (a fixed-dose combination of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide) at two doses below the 2.4 mg/2.4 mg dose used across the rest of the REDEFINE program. The results were announced on November 14, 2026, presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology. The 68-week trial randomized 309 adults with obesity, or overweight with at least one obesity-related complication, and without diabetes, at 24 sites in Canada, France, Germany, the UK and the US. Each dose was compared with pooled placebo, and the trial was not powered to compare the two doses with each other. If everyone stayed on treatment, average weight loss was 20.7% with CagriSema 1.7 mg/1.7 mg and 21.0% with 1.0 mg/1.0 mg, versus 2.0% with placebo; counting everyone regardless of stopping treatment, it was 19.4% and 18.6% versus 4.6%. Most side effects were mild to moderate and gastrointestinal; 2.9% and 4.9% stopped treatment because of adverse events, versus 4.9% on placebo, and no deaths were reported. CagriSema is not approved in the US. Novo filed with the FDA in December 2025 for the 2.4 mg/2.4 mg dose for weight management and expects a decision in the fourth quarter of 2026. The trial was funded by Novo Nordisk.

Sources

  • Novo Nordisk press release (Nov 14, 2026), CagriSema demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial: prnewswire.com
  • The Lancet Diabetes & Endocrinology (Nov 14, 2026), Wharton S, et al., Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1.7 mg each and 1.0 mg each in adults with overweight or obesity (REDEFINE 9): doi.org (abstract on PubMed)
  • ObesityWeek 2026 abstract, Poster-344, REDEFINE 9: Effect of CagriSema 1.7 mg/1.7 mg and 1.0 mg/1.0 mg in Adults with Overweight or Obesity: planion.events
  • ClinicalTrials.gov, NCT06388187 (REDEFINE 9): clinicaltrials.gov

Cover: original code-generated illustration (no photo).

This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.

Visit glp1newspaper.com for today's stories and free email alerts.

All episodes of GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.